Search results
As a member of a leading Indian pharma company, you will have the opportunity to see your ideas come to light, rub shoulders with the best of talent, work in a professional environment and see your career soar at Zydus Group. Zydus is an equal opportunities employer. We treat all job applicants fairly and do not support any form of unlawful ...
Jun 23, 2022 · Zydus Lifesciences Limited Buyback (Zydus Lifesciences Buyback) Detail. Zydus Lifesciences Limited is a leading Indian Pharmaceutical company that offers healthcare services globally. The company manufactures formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products as well as wellness ...
Oct 11, 2022 · Previously known as Cadila Healthcare Limited, Zydus Lifesciences Limited, an Indian multinational pharma company is primarily engaged in the manufacture of generic drugs. Founded in 1952 by Ramanbhai Patel, Zydus Lifesciences Limited has its corporate office in Ahmedabad (Gujarat), India.
6 days ago · Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations.
We efficiently manage the Fresh water consumption at manufacturing plants through continuously monitoring, reviewing and optimising process modifications and adoption of new technologies. In FY 2021-22 water dependency on ground water usage reduced to 34%. Compare to 55.75% for FY 2020-2021. Environmental Indicator.
Get Quote. quote options Equity T+1 Equity T+0 Derivatives MF/ETFs Debt/Others Currency Derivatives Commodity Derivatives Electronic Gold Receipts Hybrid Security Municipal Bonds SSE. Industry Classification of { {ScripHeaderData.Cmpname.FullN}} ( { {CompData.SecurityCode}}) Sector. : { {CompData.Sector}} Industry. :
Zydus Lifesciences Limited Pankaj R. Patel Chairman Dear Shareholders, It gives me immense pleasure to present our annual report for the fiscal year 2022-23. We continue to evolve as an innovation-driven lifesciences company to bridge the unmet healthcare needs of patients in India and other global markets. When a Company transforms
